China SXT Pharmaceuticals Debt to Equity

China SXT Pharmaceuticals (SXTC) currently reports a debt-to-equity ratio of 0.04. That is below the Consumer Discretionary sector average of 0.76. Use the charts on this page to explore China SXT Pharmaceuticals's debt-to-equity ratio history and peer comparisons.

China SXT Pharmaceuticals's debt-to-equity ratio of 0.04 is lower than the Consumer Discretionary sector average of 0.76. That is roughly 94.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates China SXT Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 0.04, SXTC can look expensive or cheap only in context — versus its own history, growth rate, and Consumer Discretionary peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 0.04, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is 0.76. From there, open related valuation or income-statement pages for China SXT Pharmaceuticals, and consider following SXTC for alerts when major investors trade the stock.

China SXT Pharmaceuticals is classified in the Consumer Discretionary sector. On debt-to-equity ratio, it currently shows 0.04 versus a sector average near 0.76. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing SXTC with unrelated industries.